Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.

Pharmacotherapy - 1 Sept 2017

Vela Cory M, Knepper Todd C, Gillis Nancy K, Walko Christine M, McLeod Howard L, Hicks J Kevin

Abstract excerpt

INTRODUCTION: Moffitt Cancer Center's Personalized Medicine Clinical Service (PMCS) reviews somatic next-generation sequencing (NGS) assay results, provides interpretations, and identifies potential therapeutic options. The number of individuals reviewed by our clinical service who are eligible for on-label or off-label drug therapy based on genetic test results has previously not been quantitated. We determined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Precision Medicine

Share to United States

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 28235141
DOI: 10.1002/phar.1917

Genes

ALK
BRAF
BRCA1
BRCA2
EGFR
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.PMID 28235141Read ↗

Real-world data of off-label drug use in patients with actionable genomic alterations on next-generation sequencing.Semantic proximity Read ↗

Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?Semantic proximity Read ↗

Real-World Data of Off-Label Drug Use in Patients with Actionable Genomic Alterations on Next-Generation SequencingSemantic proximity Read ↗

Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort.Semantic proximity Read ↗

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.Semantic proximity Read ↗

Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing PanelSemantic proximity Read ↗

Impact of tumor sequencing on the use of anticancer drugsSemantic proximity Read ↗

Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.Semantic proximity Read ↗

Integrative omics analyses broaden treatment targets in human cancer.Semantic proximity Read ↗

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologySemantic proximity Read ↗

Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University ExperienceSemantic proximity Read ↗

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.